Hey there. STAT reporter Andrew Joseph here welcoming you to Wednesday’s edition of Pharmalittle, with Pharmalot himself off for the day. We’re based here in
Tag - Biotech
In a study reported Thursday, a medicine from Bristol Myers Squibb nearly doubled the treatment benefit compared to standard therapy for certain patients with
Shareholders in the DNA-sequencing firm Illumina on Thursday voted to replace the company’s chairman with a candidate put forward by the activist investor Carl
The Food and Drug Administration is delaying by one month a decision on the approval of a gene therapy for Duchenne muscular dystrophy, the treatment’s maker
Terry Horgan, the 27-year-old patient who died eight days after receiving a CRISPR therapy custom-built for him, likely suffered a fatal innate immune response
On Friday, the Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee will meet to discuss the Biologics License Application for
On Friday, a committee of advisers to the Food and Drug Administration will meet to discuss Sarepta Therapeutics’ closely watched experimental gene therapy for
Amid rising demand for drugs like Wegovy, Ozempic, and Mounjaro that can lead to significant weight loss, some obesity experts are concerned about the drugs’
Jennifer Doudna may be just months away from seeing the first CRISPR-based therapy gain approval, but sitting on stage Thursday, the Nobel laureate sounded as
Gilead Sciences is famous — or perhaps, notorious — for its cure for hepatitis C. But the pharma giant believes the foundation of its company will continue to
